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Summary: We review the current knowledge of the epidemiology, clinical presentation,
diagnostics, management, infection prevention, and preparedness for children with SARS-
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CoV-2 infections, listing resources, outlining research opportunities, and advocating for the
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unique needs of children in COVID-19 pandemic response.
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ABSTRACT
Understanding the role that children play in the clinical burden and propagation of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for novel coronavirus
(COVID-19) infections is emerging. While the severe manifestations and acute clinical
burden of COVID-19 has largely spared children compared to adults, understanding the
epidemiology, clinical presentation, diagnostics, management, and prevention opportunities
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as well as the social and behavioral impacts on child health is vital. Foremost is clarifying the
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contribution of asymptomatic and mild infections to transmission within the household and
community and the clinical and epidemiologic significance of uncommon severe postinfectious complications. Herein we summarize the current knowledge, identify useful
resources, and outline research opportunities. Pediatric infectious disease clinicians have a
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unique opportunity to advocate for the inclusion of children in epidemiological, clinical,
treatment and prevention studies to optimize their care, as well as to represent children in
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the development of guidance and policy during pandemic response.
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EPIDEMIOLOGY
In December 2019, Coronavirus Disease 2019 (COVID-19) emerged in Wuhan, China, and
the etiology was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). By the end of January 2020, the World Health Organization (WHO) declared COVID-19 a
public health emergency of international concern, and by mid-March 2020, the outbreak was
declared a pandemic. Initially, children comprised between 1 to 2% of the laboratory
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confirmed SARS-CoV-2 detections among people in China [1], Italy [2], and the United

States [3]. Initial reports from the Centers for Disease Control and Prevention (CDC) noted
that the following age distributions: 15-17 years (32%), 10-14 years (27%), 5-9 years (15%),
1-4 years (11%), and <1 year (15%), with a median age of 11 years [3]. Subsequent
assessments, as access to diagnostic testing increased, demonstrated that children, defined
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in this cohort as birth to 19 years of age, comprised 5.2% of the laboratory confirmed test
results submitted to the from 22 January – 30 May 2020 [4]. Among this subsequent

M

surveillance effort, specimens from children from birth through 9 years of age comprised

d

1.5% of the total positive results while those from 10 through 19 years of age comprised

pt
e

3.7% of the total 5.2%. Internationally, most children who met either a laboratory or clinical
definition for detecting SARS-CoV-2 or having a COVID-19 have been school-aged and
adolescents. The low proportion of confirmed infections in infants and younger children

ce

probably results from the propensity of infants and young children to have mild symptoms

Ac

and thus remain undetected [5]. A retrospective cohort study of contacts of patients with
COVID-19 in Shenzhen, China found similar infection attack rates across pediatric age
groups. Among children 0-9 years, the secondary attack rate was 7.4% (95% confidence
interval (CI) 4.2-12.8) and among those 10-17 years of age, the secondary attack rate was
7.1% (95% CI 3.3-14.6) [6]. In a household transmission study in Guangzhou, China,
researchers reported that the risk of household infection was lower in the youngest age
group (<20 years; odds ratio [OR] 0.23 [95% CI 0.11-0.46]) compared with household
contacts over 60 years of age [7]. Challenges with interpretation of epidemiological studies in
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children include the variation among upper limit age parameters for classification as a child,
varying clinical and laboratory parameters for classifying as a related infection, and a lack of
representative samples from both symptomatic and asymptomatic children. These factors
likely impact differences in the descriptive epidemiology of children with COVID-19.
Estimates of R0 have varied across studies. Like factors impacting epidemiological
classification, the setting, degree of crowding, adherence to controls measures, and extent
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of diagnostic testing affect R0 estimates. Data from China early in the epidemic suggesting a
median R0 of 2-3 are widely accepted [8]; however, recent modeling suggests that the R0
value may be much higher at 5.7 (95% CI 3.8–8.9) [9].

The incubation period of SARS-CoV-2 is estimated to be 5.2 days (95% CI 4.1 to 7.0 days),

an

with a range of 2- 14 days [10] [11]. Failure to account for transmission from mildly

symptomatic individuals makes defining the incubation period in children more challenging.

M

Transmission is primarily through respiratory droplets or close contact [12]. The contribution
of transmission via aerosolized particles remains controversial. Transmission from pre-
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symptomatic (within 48-72 hours before signs and symptoms appear) [13, 14] and

pt
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asymptomatically [15] infected children have been suggested [16]. This has also been
observed with influenza [17], and other respiratory viral infections, when asymptomatic or

ce

sub-clinically infected children elude case detection. Case series suggest that the majority
(80-84%) of infected children have a symptomatic adult household or other direct

Ac

epidemiologic close contact [18].
There are reasons to suspect that children may represent an important reservoir of infection
within the community, especially those with higher viral loads who escape recognition
because they manifest less severe disease [19] [20]. Although symptomatic children have
demonstrated higher viral loads from nasopharyngeal specimens than asymptomatic
children [21] an understanding of how viral load corresponds with transmission is evolving.
Detectable SARS-CoV-2 from the nasopharynx for up to 22 days following symptom onset
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and for up to 30 days following symptom onset from pediatric fecal samples demonstrates
the challenge of interpreting the significance of prolonged and variable shedding from
different anatomical sites [18, 22] [23]. The association seen in adults of a greater severity
of disease with higher viral loads and longer shedding of SARS-CoV-2 may not hold in
children [24]. Moreover, polymerase chain reaction (PCR) detection of viral RNA may not
represent infectious virus particles. The ongoing accumulation of information related to
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will add to our understanding of transmissibility in recovered children [25].

t

serological correlates of protection following both symptomatic and asymptomatic infections

UNDERLYING CONDITIONS AND CLINICAL FEATURES

Underlying health conditions are common in hospitalized children with acute COVID-19,
including chronic respiratory insufficiency, obesity, and neurodevelopmental conditions [4]
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[26] [27] [28]. It is unclear whether the increased hospitalization rate among children with
underlying medical conditions is due to a lower threshold for hospitalization, concern for

M

complications, or more severe manifestations of a SARS CoV-2 infection.
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Several case series have described the clinical features of SARS-CoV-2 infection in children
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from the perspective of disease severity, presenting symptoms, and in comparison to those
described in adults. A consistent picture of a generally mild disease in children has emerged
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from settings in Asia, North America, and Europe. More than 96% of children reported to the
equivalent of the Chinese CDC with laboratory confirmed SARS-CoV-2 infections had mild
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or moderate illness (fever, respiratory symptoms, or radiographic pneumonia without
hypoxemia). Less than 3% had severe disease requiring oxygen supplementation and < 1%
(3 children) were considered to be critically ill [29]. In several case series, most children were
identified based on symptoms, making rates of infection in asymptomatic children unknown.
Among 17,877 children who had symptoms reported to the U.S. CDC, the most common
symptoms were fever (46%), cough (37%), headache (15%), diarrhea (14%), and sore throat
(13%) in children < 9 years and headache (42%), cough (41%), fever (35%), myalgia (30%),
sore throat (29%), shortness of breath (16%), and diarrhea (14%) in children 10 – 19 years
8

of age. Other less commonly reported symptoms included rhinorrhea, nausea/vomiting,
abdominal pain, and anosmia and dysgeusia [4]. Among a cohort of 50 hospitalized children
(< 21 years of age) in New York City, the median time from symptom onset to hospitalization
was 2 days with a median length of hospitalization of 3 days. Forty (80%) had fever and 32
(64%) respiratory symptoms with infants less likely to have respiratory symptoms compared
with older children. Sixteen (8%) had a viral co-detection and 20 (40%) had a presumptive or
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confirmed bacterial co-infection. Sixteen (32%) required respiratory support and 9 (16%)
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required assisted ventilation [30]. A cohort of 65 children receiving care in a New York City
area health system demonstrated similar demographics with 35% of patients requiring
intensive-care-unit care. Severity was lowest in infants < 60 days of age and highest in
chronically ill children; 79% of immunocompromised children had mild disease. One death
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was reported [28]. In comparison, a multinational systematic review of clinical information
from 1780 children noted fever (52%), cough (47%), sore throat (18%) and severe illness in

M

0.6% [26].
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As the pandemic progressed, the ability of SARS-CoV-2 infection to result in a broad
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spectrum of pathological conditions with varying clinical manifestations has become
apparent. In April 2020 several European countries noted increasing numbers of children
with systemic inflammation and clinical features resembling both Kawasaki Disease and
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toxic shock syndrome. Simultaneously, reports from the U.S. began to describe the clinical

Ac

characteristics, treatment, and outcomes of previously healthy SARS-CoV-2-infected
children and adolescents with inflammation in multiple systems [31]. Initially termed the
Pediatric Multi-System Inflammatory Syndrome Potentially Associated with COVID-19 [32],
the CDC developed a case definition for what is now referred to as Multisystem Inflammatory
Syndrome in Children (MIS-C) in North America. Publicized in a health alert disseminated in
the U.S., https://emergency.cdc.gov/han/2020/han00432.asp, the clinical and laboratory
parameters of children who meet the criteria for MIS-C differ from those with Kawasaki
Disease. Children with MIS-C are usually older, have more symptoms consistent with clinical
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shock, have involvement of their gastrointestinal and cardiovascular systems, and have
lymphopenia with notably elevated inflammatory markers. Coronary artery aneurysms have
been noted both in children < 5 years old who were more likely to have presentations similar
to those seen with Kawasaki Disease, as well as in older children [33, 34]. One of the first
case series to be described in the U.S consisted of 6 critically ill children with fever, diarrhea,
shock, with variable skin lesions, conjunctivitis, extremity edema, and mucous membrane
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changes [33]. A more recently studied cohort of 186 children presenting with MIS-C had a
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mean age of 8.3 years; the majority (73%) were previously healthy and 130 (70%) had

laboratory evidence of a SARS-CoV-2 infection via PCR and/or serum antibody testing. In
the U.S. cohort, gastrointestinal (92%), cardiovascular (80%), hematologic (76%)

mucocutaneous (74%) and respiratory (70%) symptoms were reported; 80% required
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intensive care with 4 deaths [35]. A cohort of children identified in New York had similar
findings, with an increase in MIS-C cases noted 1 month following a peak of SARS-CoV-2

M

infections in the state [34]. A case series from a single center in London described 4 (15%)
children with MIS-C who had new neurological symptoms involving both the central and

d

peripheral nervous systems with splenial changes on imaging, in the absence of respiratory

pt
e

symptoms. Complete neurological recovery was noted in two of the children with ongoing
monitoring of the improving neurological status of the other two children. Three of the 4

ce

children received intravenous immunoglobulin (IVIG); two of whom also received biologics
[36]. Guillain-Barré Syndrome has been associated with COVID-19 in two case reports. The

Ac

first occurred three weeks following a mild febrile and respiratory SARS-CoV-2 infection in
an 11-year-old male [37] and a second was coincident with a SARS-CoV-2 presentation in a
15-year old male [38]. Neurotropism of the SARS-CoV-2 virus may explain these
manifestations with a temporal relationship to COVID-19 infections in children.
Unusual symptoms have been recognized as likely related to COVID-19. Children and young
adults have presented with painful purple and red papules on their fingers and toes, similar
to pernio, which has been termed ―COVID toes‖, as their only manifestation of COVID-19

10

[39]. Anosmia with or without dysgeusia has recently been incorporated into the list of
symptoms associated with COVID-19 [40] but both are less commonly reported in children
[28], possibly due to lack of appreciation, lack of reporting, or true absence. Several
children’s hospitals in the U.S. have collaboratively developed a registry for the standardized
collection of clinical and epidemiologic information from children with COVID-19. This
centralized source of information will help to characterize many aspects of COVID-19

t

disease manifestations in children (https://www.pids.org/news/764-usa-pediatric-covid-19-
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registry.html).
Laboratory and Radiographic Findings

Early reports from China noted leukopenia (19%), lymphopenia (31%), transaminitis (6%),

an

elevated myocardial enzymes (31%) and elevated C-reactive protein (CRP) (3%) among
children with SARS-CoV-2 infections [41]. Cytokine abnormalities have been described in

M

children with severe manifestations of COVID-19, including elevated levels of interleukin (IL)6, IL-10, and Interferon-gamma (IFN-ɣ) [42]. A European systematic review of 655 children

d

with mild to moderate clinical manifestations of COVID-19 noted lymphopenia or neutropenia
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in 13% and elevated inflammatory markers in 31% [26]. Among two cohorts of hospitalized
children < 21 years of age in the New York City area with laboratory confirmed SARS-CoV-2

ce

detected via PCR, between 44 to 72% had lymphopenia and inflammatory marker
abnormalities; coagulopathy was correlated with a more severe disease presentation [30]

Ac

[28].

The most common imaging abnormalities noted among Chinese children with both
symptomatic and asymptomatic COVID-19 were pulmonary ground glass opacities or
consolidation [43]. In a case series of 171 children from whom SARS-CoV-2 was detected,
56 (33%) had ground-glass opacities, 32 (19%) had local patchy shadowing, 21 (12%) had
bilateral patchy shadowing, and 2 (1%) had interstitial abnormalities [44]. Another series
found that bilateral infiltrates were more common than unilateral infiltrates; 4 (20%) children
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had normal initial chest computerized tomography (CT) imaging [45]. Although children with
more severe manifestations of disease were more likely to have imaging abnormalities [41],
this association may be due to ascertainment bias, as children with severe manifestations
may be more likely to undergo imaging. Additionally, imaging abnormalities have been
described in children with minimal to no recognized symptoms.
Outcomes
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Most children with severe manifestations of COVID-19 completely recover. Accounting for
access to diagnostic testing, children with underlying conditions appear to be most at risk for
adverse outcomes. The spectrum of outcomes is described among 48 children cared for in
pediatric intensive care units (PICU) in North America, 40 (83%) had an underlying medical
condition. Although 18 (38%) of these children required mechanical ventilation and one

an

patient required extracorporeal membrane oxygenation, the overall mortality was 4% among
this North American PICU cohort [27]. In a case series from New York City, obesity and

M

asthma were prevalent in the cohort but not significantly associated with PICU admission

d

[46]. Prolonged courses of critical care have been reported in China for children with acute

pt
e

lymphocytic leukemia, hydronephrosis, and intussusception [42, 44, 47, 48].
These generally favorable outcomes among children who experience clinically significant

ce

COVID-19 is an area of active exploration. Hypotheses that may explain the decreased
severity of disease in children compared with adults include the lower expression of the

Ac

angiotensin converting enzyme 2 (ACE 2) viral entry receptor in the lungs and nasal epithelia
of children compared to adults [49] [50], differences in innate immune responses that control
viral killing and expression of inflammatory regulators involved in the ARDS pathway [51,
52], cross protection from non-novel coronaviruses, exposure to vaccines with
immunomodulating properties [53], and the lower prevalence of underlying chronic medical
conditions compared to adults and the elderly with COVID-19 [54].
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SPECIAL POPULATIONS
Pregnant women: While developing an understanding of the impact of SARS-CoV-2 on
pregnant women and their neonates, professional societies including the American College
of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine have issued
joint guidance [55] and registries have been developed to track outcomes of infected
pregnant women and their infants (https://priority.ucsf.edu/). The American Academy of
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Pediatrics (AAP) issued guidance for the care of newborns born to women with suspected or
confirmed COVID-19 [56].

Routine testing for SARS-CoV-2 in women in a high prevalence city in the U.S., at the time
of delivery of their infants, showed that one in eight women from whom SARS-CoV-2 was

an

detected at the time of delivery, were asymptomatic [57]. Initial reports did not suggest a
higher mortality or increased rates of complications among pregnant women from whom

M

SARS-CoV-2 was detected [58] [59, 60]. Subsequently, ongoing CDC surveillance has noted
that pregnant women in the U.S. with SARS-CoV-2 infections were more likely to be

d

hospitalized than non-pregnant women for non-obstetric indications. Adjusting for
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e

cofounders, pregnant women were more likely to be cared for in an intensive care unit and to
receive mechanical ventilation than non-pregnant women of childbearing age. Among 81%

ce

of 11,312 pregnant women with SARS-CoV-2 detection for whom information was available,
50% were of Hispanic or Latino ethnicity, 23% were White race and non-Hispanic ethnicity,

Ac

20% were Black race and non-Hispanic [61]. A high rate of acute respiratory distress
syndrome was observed among a cohort of 64 pregnant women with severe or critical
COVID-19 in the U.S. Half of the women were delivered during their third trimester; most of
the infants born to the critically and severely ill women were premature. However, there were
no maternal nor perinatal deaths in this cohort [62].
Evidence for vertical transmission of SARS-CoV-2 has been sought from maternal-neonatal
pairs. A case series of 33 SARS-CoV-2 infected mothers identified 3 (9%) neonates in whom
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SARS-CoV-2 was detected from nasopharyngeal and stool specimens on days of life 2 and
4 and who had symptoms of early-onset sepsis with initial fever and pneumonia. Rapid
clinical improvement and lack of persistent viral detection made the significance of vertical
transmission unclear [63].
Probable congenital infection has been reported in an infant born via Caesarean section with
SARS-CoV-2 detected via PCR from neonatal nasopharyngeal swabs on day of life 0, 2, and
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7, from blood on day of life 4 and from stool from day of life 7; umbilical cord tissue was
negative for SARS-CoV-2. The neonate had an uneventful postnatal course and was

reportedly well at a day of life 30 follow up assessment [64]. From a case series of women
diagnosed with COVID-19, their third trimester placentas were more likely to show at least
one feature of maternal vascular malperfusion, although rates of acute and chronic

an

inflammation were not increased compared to the placentas of women without COVID-19

M

[65].

One can speculate that the endovascular effects of SARS-CoV-2 infection result in placental

pt
e

infection.

d

thrombosis and insufficiency, affecting the fetus, even in the absence of transplacental

Neonates: Preliminary analyses have suggested that in utero vertical transmission is

ce

possible from SARS−CoV−2 positive pregnant women. SARS−CoV−2 has been detected in

Ac

placentae, umbilical cord blood, vaginal mucosa of pregnant women and in expressed
human milk [66]. Other researchers have provided evidence supporting probable congenital
transmission from women without active infection at the time of delivery [64]. Guidance
regarding the management of the infant born to a woman with known or suspected COVID19 or asymptomatic detection of SARS-CoV-2 virus has undergone evolution. The initial
suggestion of mother-infant separation was subject to debate, with the AAP [67], the U.S.
CDC [68], and the WHO [69] all suggesting different approaches. Recent revisions by the
AAP, based on accumulated data and experience, have harmonized guidance [56]. Between
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2-5% of over 1500 infants registered in the Perinatal COVID-19 Registry tested positive in
the 24-96 hours following birth [56]. Noting that the risk for neonatal acquisition of SARSCoV-2 appears to be equivalent when rooming-in with maternal adherence to infection
prevention guidance, versus physical separation of women and their neonates, post-partum
women may be offered the choice of rooming-in. Infants requiring hospitalization before 1
month of age have been found to have symptoms consistent with COVID-19 and SARS-

t

CoV-2 has been detected in their nasopharyngeal specimens. The relationship between
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maternal and caregiver exposure and neonatal acquisition of infection is an area of ongoing
investigation.

Although SARS-CoV-2 nucleic acid has been detected in expressed human milk, the viability
of virus and the presence and role of antibodies to SARS-CoV-2 is currently unknown. To
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date, SARS-CoV-2 transmission has not been documented via human milk ingestion,
therefore expressed human milk or direct breastfeeding is supported for women with COVID-

M

19. Hand and breast hygiene along with maternal masking is also recommended to

d

decrease opportunities for transmission of SARS-CoV-2 from mother to neonate.
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The AAP continues to recommend diagnostic testing of all asymptomatic newborns at 24
and, if still hospitalized, at 48 hours of age [67] [56]. While the results of universal testing of

ce

asymptomatic neonates may have utility for in-hospital isolation and for understanding the
epidemiology of COVID-19 in this low risk population, the implications of test results for post-

Ac

hospital pediatric care should be considered. Additional guidance from the AAP regarding
hospital visitation and discharge of neonates born to mothers with COVID-19 may be found
at https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinicalguidance/
Immunocompromised: Our current understanding of the risk for SARS-CoV-2 acquisition
and subsequent COVID-19 in immunocompromised children reflect limited epidemiologic
data. Assumptions about the elevated risk for infection and adverse outcomes in
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immunocompromised children is based on extrapolation from experience with other
respiratory viruses [70] . The duration of viral shedding may be prolonged in those receiving
immunosuppressive therapies.
Considerations relevant to the care of children with cancer [71], those who have undergone
hematopoietic cell transplant (HCT)[72, 73], or solid organ transplants (SOT) [74] are
emerging but are mostly adult focused. Accumulating evidence suggests that mild to
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moderate immunosuppression may not be a risk factor for more severe manifestations of
COVID-19 in children [28] [75] [76].

Given the current pandemic, a high level of clinical suspicion for COVID-19 in
immunocompromised children is needed. Societies dedicated to the care of

an

immunocompromised persons recommend that children with fever or respiratory symptoms
(cough, shortness of breath, hypoxemia) be considered for SARS-CoV-2 PCR testing. If

M

children have respiratory symptoms, multiplex respiratory panels should also be considered.
An immunocompromised child with symptoms consistent with COVID-19 with a negative

d

SARS-CoV-2 PCR may be considered for repeat testing if clinical suspicion for COVID-19
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remains high, given variability in screening test sensitivity and specificity. Lastly, children
positive for SARS-CoV-2 with lower respiratory symptoms should be considered for chest

ce

imaging if the result of the imaging study will impact their management. Given the
heterogeneity of the immunocompromised pediatric population and the rapidly evolving

Ac

nature of the COVID-19 pandemic, a list of organizations and their associated COVID-19
websites is provided as reference for the most updated information regarding management
(Table 1).

DIAGNOSTICS
Diagnosis of acute SARS-CoV-2 infection is a rapidly evolving field. Most assays utilize
specific real-time RT PCR techniques [77, 78]. Numerous PCR assays approved only under
the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) have been
16

extensively used in children [18, 29, 63, 79]. Although the nucleocapsid gene has been the
primary target, some assays have included other viral target sequences [73, 78]. Molecular
testing is the optimal diagnostic test for detection of SARS-CoV-2 in a person suspected of
having an acute COVID-19.
For diagnostic testing for SARS-CoV-2, CDC recommends collecting and testing an upper
respiratory specimen, preferably a nasopharyngeal specimen [80]. The diagnostic utility of
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saliva specimens, antigen testing, and self-collected nasal specimens are being assessed in
adults and will need to be validated in children. Non-respiratory sites, including stool, have
been evaluated in infants and children using research-based assays to detect SARS-CoV-2
RNA, but FDA EUA approved commercially available assays are currently not available for
stool specimens. To conform to EUA guidance, users should note the anatomical sites for

an

which an approved SARS-CoV-2 assay is validated.

M

Antibody assays that detect IgM and IgG may be reactive as early as 4 days after symptom
onset [54], until as late as 11-14 days from date of infection [81], impacting the utility of

d

serology as a diagnostic modality. Serological assays approved under the FDA EUA [82]

pt
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have largely used adult specimens for validation and raise the question about applicability in
children, especially with respect to cross-reactivity to the non-novel coronaviruses [83].
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Serologic assays may be helpful to describe the epidemiology of SARS-CoV-2

Ac

retrospectively, but population samples will be a key factor in interpreting the results.
Although detection of another respiratory virus does not eliminate the possibility of SARSCoV-2 co-infection, at the beginning of the pandemic, many public health entities suggested
that detection of a non-SARS-CoV-2 respiratory organism was enough evidence to exclude
a COVID-19. In part, this triage system was based upon limited access to acute diagnostic
capability at the time, which also coincided with an end to the respiratory viral season.
Among 161 hospitalized children (≤14 years of age) with positive respiratory virus PCR
assays enrolled in a retrospective study, two (1%) were coinfected with human respiratory
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viruses and Mycoplasma pneumoniae in China. These organisms were detected in the
bronchoalveolar lavage fluids from both patients [84]. Another case series from China
suggested that 17 (50%) children had nasopharyngeal co-detection of SARS-CoV-2 with
other respiratory viruses [85]. Understanding coinfection and codetection of organisms with
SARS-CoV-2 in children is one of ongoing interest. Particularly as the pandemic extends into
the winter viral season in the northern hemisphere, consideration of other respiratory viruses
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may inform management decisions.
Consideration of the sensitivity, specificity, positive and negative predictive values of
diagnostic assays is essential. Despite low limits of detection of viral RNA in most

commercially available PCR assays, false negative and discordant results have been noted
[86]. As with any assay, timing of collection with respect to the illness course, intermittent

an

shedding, variability of sample collection, degradation of viral RNA during shipping or
storage of samples, the specimen acquisition site, and host and epidemiological factors must

M

be considered in the interpretation of diagnostic test results.

pt
e

d

TREATMENT AND PREVENTION
Management of children with acute SARS-CoV-2 infection and post-infectious sequelae
such as MIS-C is rapidly evolving, with guidance available from CDC [87], WHO [88] the

ce

National Institutes of Health (NIH) [89], and the Infectious Diseases Society of America

Ac

(IDSA) [90]. The Pediatric Infectious Diseases Society (PIDS) developed guidance that
focuses on the rationale and indications for the use of antivirals with known or suspected
COVID-19 in children [91]. Supportive care remains the mainstay of management for most
children. A summary of relevant candidate therapies is provided in Table 2. Additional
investigational COVID-19 therapeutics with ongoing or upcoming planned human trials can
be found on ClinicalTrials.gov (https://clinicaltrials.gov/ct2/results?cond=COVID-19).
Following the finding that the antiviral remdesivir was superior to placebo in shortening the
time to recovery and reducing mortality in adults hospitalized with lower respiratory tract
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involvement from a COVID-19 [92], a Phase 2/3 single-arm, open-label study to evaluate the
safety, tolerability, pharmacokinetics, and efficacy of remdesivir (GS-5734™) in children from
birth to < 18 years of age with COVID-19 was initiated (NCT04431453) and is ongoing. An
evaluation of the management of children using immunomodulatory therapies such as IVIG,
corticosteroids, IL-6 and IL-1Ra inhibitors is ongoing for children with inflammatory (MIS-C)
or severe presentations [35]
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There is currently no medical evidence to support the use of chemoprophylaxis for SARSCoV-2 infections in children. A recent randomized controlled trial showed no efficacy in the
prevention of COVID-19 in adults taking hydroxychloroquine for COVID-19 post-exposure
prophylaxis [93]. There is one ongoing trial for prevention of thromboembolism in children
with COVID-19 (NCT04354155). It is not clear whether the burden of disease warrants trials

an

of monoclonal antibody prophylaxis in immunocompromised children who may not respond

M

adequately to a vaccine.

There are currently no licensed vaccines available to prevent COVID-19. Over 140 vaccine

d

candidates targeted at COVID-19 prevention are in development, with many in ongoing

pt
e

clinical trials. Utilizing models including adjuvanted and non-adjuvanted protein-based, DNAbased, inactivated viral, and mRNA-based, viral-like particles, and viral vector-based vaccine

ce

designs, select candidates with promising phase 1 and 2 results are being evaluated in
phase 3 trials. Most vaccine trials currently exclude the enrollment of children in initial

Ac

stages, however plans are in place to extend trials of promising vaccine candidates to
pregnant women ad children.
INFECTION PREVENTION AND CONTROL
SARS-CoV-2 is spread by respiratory droplets or close contact [94] facilitating transmission
in grouped care arrangements. Person-to-person transmission as well as healthcareassociated transmissions have been described [95]. The extent of transmission by aerosols
remains controversial. The virus is not believed to be spread by food. Emerging data
19

supporting lack of infectivity with prolonged shedding after 9 to 10 days has helped to guide
isolation and quarantine guidance within healthcare settings and in the community [96] [97].
As with all infectious diseases, the principles of Identify, Isolate and Inform may be applied to
the management of children with known or suspected COVID-19. The unique aspects
related to care of children with known or suspected COVID-19 center on maintaining a
balance between family-centered care and healthcare worker safety (Table 3).
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As the epidemiology of SARS-CoV-2 and COVID-19 unfolds, the mild and varied spectra of
illness in most children makes identification challenging. Unique to children is the important
consideration of parental presence during care. To prevent transmission in facilities,
screening, triage and isolation strategies, implemented at all points of entry, should involve
accompanying family members. A high level of clinical suspicion, well-equipped triage

an

stations, routine objective and subjective screening, and signage in public areas promoting
masking with child-sized masks with child-accessible hand hygiene efforts are

M

recommended [98]. Environmental controls, including child-friendly floor markings to

d

encourage social distancing, partitioning, and physical distancing, are recommended.
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Several unique aspects for care of children during an infectious disease pandemic are
reviewed in Table 3.

ce

PREPAREDNESS AND COMMUNITY IMPACT

Ac

As part of the preparedness response, many pediatric healthcare entities have provided
resources to adult healthcare systems, given the greater clinical impact of COVID-19 among
adults. While the burden of clinical disease has been notably less in children, the
psychosocial impact has been profound. Accustomed to socialization and interaction,
children separated from their peer group have experienced the adverse effects of physical
and social distancing manifest as depression, anxiety, and loss of developmental
milestones. An estimated 188 countries imposed countrywide school closures affecting more
than 1.5 billion children [99]. While a systematic review estimated that school closures may
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contribute a 2 to 4% reduction in COVID-19 associated deaths [100], emerging evidence
supports the hypothesis that children are not the primary propagators of infection [101] [102]
and that reopening schools provides an essential service to children and their communities
[103]. The timing and extent of school reopening is a multidisciplinary decision that should
consider local epidemiology and resources, while engaging Pediatric Infectious Disease
clinicians. The CDC [104] and AAP [105] have developed guidance to assist policymakers

t

with strategies to safely open schools by optimizing infection prevention, surveillance, and
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developing inclusion and exclusion approaches in collaboration with local public health
authorities.

In addition to disruption of their peer groups, some children may have one, both, or all
caregivers debilitated by illness, resulting in interruption of delivery of care. In many

an

instances, preventive care, including immunization delivery, has been delayed [106] .

M

Non-hospital institutional systems that house or provide care to children and adolescents
may be adversely impacted by ill residents or staff. Many ambulatory group and chronic care

d

facilities for children have been unable to continue operations due to their inability to comply

pt
e

with requirements related to social distancing in the provision of care [107], resulting in
discontinuation of essential services. Transmission of SARS-CoV-2 in an overnight summer

ce

camp setting resulted in high attack rates among persons in all age groups. Asymptomatic
infection potentially contributed to undetected transmission; assessment of clinical impact is

Ac

ongoing. Use of face coverings and other preventive strategies were not universal [108].
This report also questions the utility of pre-attendance, asymptomatic SARS-CoV-2 PCR
testing, collected up to 12 days in advance of participation in a congregate activity.

CONCLUSIONS AND OPPORTUNITIES:
As we learn more about the impact of SARS-CoV-2 on children, the adults who care for
them, and the impact of management and containment strategies, questions related to the
21

management of children during a pandemic have emerged (Table 4). While we gain a
greater understanding of the clinical impact and epidemiology of SARS-CoV-2, we must
continue to advocate for the inclusion of children in clinical research, treatment, and
prevention trials. Pediatric infectious disease clinicians and researchers are uniquely poised
to partner with pediatricians, health departments, and policymakers to develop guidance that
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incorporates the unique needs of children and the communities in which they reside.
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Table 1: Resources for lay and medical caregivers on COVID-19 from organizations
and societies involved in the care of immunocompromised pediatric patients1
Resources (guidelines, newsletters, educational
Organization or Society
materials)
American Association of Blood

http://www.aabb.org/advocacy/regulatorygovernment/

Banks (AABB)

Pages/AABB-Coronavirus-Resources.aspx

us
cr
ip

t

https://www.redcrossblood.org/donateAmerican Red Cross (ARC)

blood/dlp/coronavirus--covid-19--and-blooddonation.html

American Society of Hematology

https://hematology.org/covid-19
(ASH)

http://aspho.org/covid-19-resources-for-pediatric-

Hematology/Oncology (ASPHO)

hematologists-oncologists
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American Society of Pediatric

https://nam03.safelinks.protection.outlook.com/?url=ht

d

tps%3A%2F%2Fwww.myast.org%2Fcovid-19-
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e

information&amp;data=02%7C01%7Cashane%40em
ory.edu%7C880396cd6b8f4b17cada08d83ac09447%

(AST)

7Ce004fb9cb0a4424fbcd0322606d5df38%7C0%7C0
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ce

American Society of Transplantation

%7C637323946089322541&amp;sdata=pr1Ka0Swe
WpRS%2FJfL4oherv0LRSMKwRxXPSftI5ReMU%3D
&amp;reserved=0
https://www.astct.org/communities/public-

American Society for Transplantation
home?CommunityKey=d3949d84-3440-45f4-8142and Cellular Therapy (ASTCT)
90ea05adb0e5
Center for International Blood &
Marrow Transplant Research

https://www.cibmtr.org/Covid19/Pages/default.aspx

(CIBMTR)
38

Children’s Oncology Group (COG)

https://childrensoncologygroup.org/

Emerging Infections Task Force
(EITaF), European Society of Clinical

https://www.escmid.org/research_projects/emerging_i

Microbiology and Infectious Diseases

nfections_task_force/eitafoutbreak_news/

(ESCMID)
European Society for Blood and
https://www.ebmt.org/covid-19-and-bmt
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Marrow Transplantation (EBMT)
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https://nam03.safelinks.protection.outlook.com/?url=ht
tps%3A%2F%2Fwww.esot.org%2Forganisation%2Fc
ovid-19-

response&amp;data=02%7C01%7Cashane%40emor
European Society for Organ

y.edu%7C880396cd6b8f4b17cada08d83ac09447%7
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Transplantation (ESOT)

Ce004fb9cb0a4424fbcd0322606d5df38%7C0%7C0%
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7C637323946089322541&amp;sdata=NRvfWrjvbwQ
GhSq7rZPeRtmXhilSUpeIPz4isHgCepI%3D&amp;res

d

erved=0
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Federation for the Accreditation of

http://www.factwebsite.org/News.aspx#news-id2014

Cellular Therapy (FACT)

ce

Human Immunodeficiency Virus

Directs to IDSA COVID-19 Resource Center

Medicine Association (HIVMA)
https://primaryimmune.org/coronavirus

Infectious Diseases Society of

https://www.idsociety.org/public-health/COVID-19-

America (IDSA)

Resource-Center/

International AIDS Society (IAS)

https://www.iasociety.org/covid-19-hiv
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Immunodeficiency Foundation (IDF)

International Pediatric Transplant
Directs to TTS and TID COVID-19 websites
Association (IPTA)
International Society for Heart and

https://ishlt.org/covid-19-information
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Lung Transplantation (ISHLT)
https://www.jmf-melbourne.org.au/news-andJeffrey Modell Foundation (JMF)
events/2020/3/12/covid-19-update
Leukemia & Lymphoma Society
https://www.lls.org/public-health/coronavirus
(LLS)
https://www.cancer.gov/contact/emergencyNational Cancer Institute (NCI)

t

preparedness/coronavirus
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National Comprehensive Cancer

https://www.nccn.org/covid-19/
Network (NCCN)

https://network.bethematchclinical.org/news/nmdp/be-

(NMDP)

the-match-response-to-covid-19/

Organ Procurement and Transplant

https://optn.transplant.hrsa.gov/governance/policy-

Network (OPTN)

notices/

an

National Marrow Donor Program

M

Pediatric Infectious Diseases Society

http://www.pids.org/resources/covid-19.html

(PIDS)

d

Pediatric Transplantation and

ce

(PTCTC)
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e

Cellular Therapy Consortium

None

https://tts.org/index.php?option=com_content&view=a

Ac

The Transplantation Society (TTS)
rticle&id=692&Itemid=115
https://tts.org/tid-about/tid-presidents-message/23-

Transplant Infectious Diseases (TID)
tid/tid-news/657-tid-update-and-guidance-on-2019-

Section, The Transplantation Society
novel-coronavirus-2019-ncov-for-transplant-id-

(TTS)
clinicians
United Network for Organ Sharing
https://unos.org/covid/
(UNOS)
World Marrow Donor Association

https://share.wmda.info/display/LP/COVID-19+-
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(WMDA)
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Table 2: Status of therapeutic options and ongoing clinical trials on specific antiviral
agents for treatment against COVID-191
Therapeutic

Possible

Evidence

Evidence

Additional

Current

mechanis

for anti-

for anti-

considerations

status

m of

coronavirus

SARS-

action

activity

CoV-2

Inhibition

Limited data on

Recent

an

remdesivir

of viral

pediatric use from

U.S. Food

adenosine

demonstrate

replication

Ebola treatment

and Drug

analog

s inhibitory

demonstra

trials and individual

Administra

leading to
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ted in vitro

case reports of

tion (FDA)

impairmen

against

[115]

pediatric use [116]

Emergenc

t of viral

multiple

Significantl

[117]

y Use

replication

human

M

coronavirus

y

Authorizati

shortened

on (EUA)

delayed

strains [110]

recovery

for

chain

[111] [112]

time in a

hospitalize

terminatio

[113]

randomize

d adult

n [109]

In a MERS-

d

and

CoV mouse

controlled

pediatric

model,

trial of

patients

remdesivir

hospitalize

requiring

improved

d adults

oxygen,

lung

[92]

mechanic
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via
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In vitro,

an

Prodrug of

d

Remdesivir

t

activity

function,

al

decreased

ventilation,
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or ECMO.

viral loads,

Phase 2/3

and

pediatric

decreased

trial

lung

enrolling

pathology

(NCT0443

compared to

1453)

t

pulmonary
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ip

untreated
mice [112,
113] In a
MERS-CoV

primate

an

non-human

esivir

M

model, remd

d

treatment
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e

decreased
clinical
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disease
scores,
decreased
pulmonary
viral loads,
and
decreased
lung
pathology
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compared to
untreated
controls
[114]
Corticosteroi

Generalize

Widely used

Rates of

Limited pediatric

Currently

ds

d anti-

among

ARDS,

data

available

ry activity

patients with

need for

SARS and

respiratory

MERS

support
were

for use for

t

shock and

multiple

us
cr
ip

inflammato critically ill

conditions

an

higher in
patients

M

on
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e

d

steroids
but
steroids
were only
used for
those with
more
severe
illness:
unclear if
there was
benefit
[118]
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Dexameth
asone
reduced
deaths by
1/3 in
adults

t

requiring

l

us
cr
ip

mechanica

ventilation

and by 1/5

an

in adults

receiving

M

suppleme

Convalescen

Ac

oxygen
[119]

Human

In a

Available for

Multiple

convalesc

randomize

children via a

trials in

ent plasma

d trial of

national expanded

progress

is
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access protocol

available

patients,

https://www.uscovid

from

convalesc
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recovered
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and can

provide
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statistically
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significant
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improvem

g

ent. Trial
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bulin-

early and

containing

may have

plasma

been
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donate
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ered [120]

Altered

In vitro,

Hydroxychlor

glycosylati

chloroquine

oquine +/-

on of the

inhibits viral

azithromycin

ACE2

replication of

receptor

The FDA warns

Currently

against use in

available

nal study

unmonitored

for use in

showed

settings, due to the

treating

multiple

neither

potential for

malaria

coronavirus

overall

arrhythmias,

and

decreased

strains,

benefit nor

especially with QT

rheumatol

viral entry

although the

harm [129]

prolonging
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medications

disorders.
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d
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observatio
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A large
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Chloroquine/

due to

effect may

impaired

be lost if the

Currently

acidificatio

drug is

recommen

n of

added

ded to be

endosome

several

administer

[121, 122];

hours post-

ed only as

modulation infection

part of a

of the host

clinical

[121] [123-
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trial due to

response

Hydroxychlor

lack of

oquine

efficacy

inhibits

against

SARS-CoV

SARS-

and MERS-

CoV-2 in

CoV in vitro

studies to
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immune

1

date [130]
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COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome

an

coronavirus 2; hCoV OC43, human coronavirus OC43; MERS-CoV, Middle East respiratory
syndrome coronavirus; CYP3A4, cytochrome P450 3A4; RSV, respiratory syncytial virus;

M

SARS, severe acute respiratory syndrome; MERS, Middle East respiratory syndrome;
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ARDS, acute respiratory distress syndrome
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Table 3: Unique Aspects of Pediatric Infection Prevention and Management for
Children Known or Suspected to Have COVID-19
AMBULATORY

Limit family members to essential

to assist with triage upon arrival

caregivers

Limit family members present

Screen accompanying family members

Screen accompanying family

daily for symptoms and fever

members as well as patient

t

Pre-screen for symptoms prior to visit

us
cr
ip

IDENTIFY

INPATIENT

Mask symptomatic, if not subject to
universal masking
Emphasize hand hygiene

with patient

diagnostic test result (if done)

an

Isolation based on symptom and

considering patient and essential parent

services

Limit to asymptomatic essential

M

Limit activities in clinic to essential

pt
e

Limit aerosol generating procedures

caregiver(s), unless end of life care

to those that are essential for care

Healthcare workers to wear personal

Healthcare workers to wear personal

protective equipment (PPE) including a

protective equipment (PPE) including

fit-tested N95 respirator for aerosol-

a fit-tested N95 respirator for aerosol-

generating procedures

generating procedures

Parents and patients > 2 years of age to

Parents and patients > 2 years of age

wear face coverings

to wear face coverings

Asymptomatic caregiver may remove

ce
Ac

Emphasize hand hygiene

Isolate family in examination room

d

ISOLATE

Universal masking

PPE in child’s room but should replace
with entrance of healthcare personnel
Cancel congregate events and close or
strictly limit access to family lounges
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Isolation status should consider both

patient and accompanying family

patient and symptoms of essential

members to assist with triage

caregiver(s)

Place isolation status indicator on

Place isolation status indicator on door

door of examination room

of patient’s room

Have PPE available exterior to room

Have PPE available exterior to room

Label and decorate PPE if

Utilize remote programing for:

decorations do not interfere with

- Music and art therapy

function

t

MANAGE

Query diagnostic testing status of

us
cr
ip

INFORM

- Behavioral therapy

- Hospital school programing
- Child life therapy and instruction

Label and decorate PPE if decorations
for not interfere with function

M

an

- Pet therapy

PPE = personal protective equipment

Ac

ce

pt
e

d

1
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Table 4: Research Opportunities Related to Children and COVID-19
Category

Question / Topic

Population

Approach

Epidemiology

Immunologic basis of

Children of all

Collect serological data pre-

relative sparing of

ages

and post-COVID-19; Compare

younger children

immunologic biomarkers in

us
cr
ip

t

COVID-19 hospitalized, mildly
asymptomatic, and

asymptomatic children

Understand the variable

Children of all

Colonization studies of various

detection of viral nucleic

ages

sites correlated with clinical

acid from
nasopharyngeal,

presentation and symptoms

M

oropharyngeal, nasal,

an

Diagnostics

Clinical

Understand the varying

Children of all

Analyze registries assembled

infectious and post-

ages;

compiling descriptive and

infectious clinical

comparison

epidemiologic data

manifestations

with adults

Ac

ce

manifestations

pt
e

children

d

and stool specimens in

associated with
infection, including MultiSystem Inflammatory
Syndrome in Children
(MIS-C)

Treatment

Engagement of children

Older

Enroll and engage older

with their unique

adolescents

adolescents in early phase
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pathophysiology and

with

trials

limited severity in

progression to

treatment and vaccine

younger age

trials from the

groups

development stage
Role of asymptomatic or

Children of all

Household and community

Prevention

mildly symptomatic

ages

transmission studies; design

t

Infection

vaccine trials with

propagation in the

us
cr
ip

children in COVD-19

consideration of herd

population

protection

Understand the impact

Children of all

Compare cohorts of different

and Impact

of social isolation and

ages

ages and from different

abrupt economic

communities.

M

changes on physical and

an

Preparedness

social development, food

pt
e

health

d

security, and behavioral

Children all

Engage pediatric infectious

messaging, optimize

ages

disease clinicians with public

Ac

ce

Distribute public health

engagement, and

health professionals in the

subsidize systems to

assessment of immunization

optimize uptake of

uptake. Collaborate with

routine pediatric

clinicians to develop safe and

vaccines and monitor for

effective outreach strategies to

disease outbreaks

immunize children during the
stages of pandemic response.
Engage the media in
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propagating productive
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messaging
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